DarioHealth (NASDAQ:DRIO) Bolsa

DarioHealth

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Movimientos destacados del premercado: Cal-Maine Foods sube un 3,8%, Sana Biotechnology lidera con un 220,6%.

Las acciones de Cal-Maine Foods suben un 4%; Aquí están 20 acciones que se mueven en el premercado

DarioHealth Corp

Citigroup analyst Andres Cardona upgrades YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) from Neutral to Buy and raises the price target from $44 to $48.

News

Upgrades

Price Target

Analyst Ratings

Citigroup Upgrades YPF to Buy, Raises Price Target to $48

Guidance

NVAX

Novavax Reiterates Expectation To Achieve R&D Plus SG&A Expenses For FY25 Of Between $475M-$525M. For 2026 And 2027, Expects To Reduce R&D Plus SG&A Expenses To Approximately $350M And $250M, Respectively

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $4,500,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

CSE:QNTM

QNTM

Quantum Biopharma Purchases Additional $1M Worth Of Bitcoin And Other Cryptocurrencies As Part Of Strategic Efforts, Bringing Total Investment In Digital Assets To $4.5M

Citigroup analyst Scott Gruber downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Buy to Neutral and lowers the price target from $25 to $19.

Downgrades

Citigroup Downgrades Helmerich & Payne to Neutral, Lowers Price Target to $19

HC Wainwright &amp; Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and lowers the price target from $12 to $11.

YMAB

HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $11

U.S. President Donald Trump has demanded a comprehensive investigation into the celebrity endorsements received by Kamala Harris during the 2024 election. He alleges that these endorsements involved illegal compensation.
What Happened:&nbsp;Trump took to his Truth Social early Monday and singled out celebrities like Bruce Springsteen, Beyoncé, Oprah Winfrey and Bono, who publicly backed Harris.&nbsp;He made claims that these endorsements were bought, which he believes is against the law.
Trump accused Harris of disguising payments for entertainment as compensation for these celebrity endorsements. He went on to label the artists who supported Harris as &#8220;unpatriotic.&#8221;
Harris&#8217; Office did not immediately respond to Benzinga&#8217;s request for comment. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="610" height="473" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png" alt="" class="wp-image-919578" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png 610w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225-300x233.png 300w" sizes="(max-width: 610px) 100vw, 610px" /></figure>
However, Politico reported that these allegations have been refuted by Beyoncé&#8217;s mother and Winfrey, who insisted that the artists did not receive any personal fees for their endorsements. Campaign finance records indicate that Harris&#8217; campaign paid $165,000 to Beyoncé&#8217;s production company and&nbsp;$1 million was paid to Winfrey&#8217;s company, Harpo Productions.
Despite raising over&nbsp;$1 billion in just a&nbsp;few months, the Harris campaign has been subject to rumors of paying millions to celebrities for their support. These rumors have been categorically denied by the celebrities&#8217; teams.
SEE ALSO: <a href="https://benzinga.com/news/global/25/05/45487501/trump-pushes-for-russia-ukraine-ceasefire-to-end-bloodbath-in-high-stakes-calls-with-russian-president-and-zelenskyy-amid-drone-attacks" target="_blank" rel="noreferrer noopener">Trump Pushes For Russia-Ukraine Ceasefire To End &#8216;Bloodbath&#8217; In High-Stakes Calls With Russian President And Zelenskyy Amid Drone Attacks</a>
Why It Matters: Trump lashed out at Bruce Springsteen last week, calling him "not a talented guy" and criticizing his appearance, after the musician labeled the Trump administration "corrupt, incompetent and treasonous" during a concert in England.
Notably, the 2024 election saw a significant increase in celebrity involvement in politics. Following Trump&#8217;s second victory, several high-profile celebrity Americans announced plans to <a href="https://www.benzinga.com/real-estate/24/11/41982378/trumps-win-has-celebrities-saying-goodbye-america-see-where-theyre-going">relocate </a>abroad in November 2024.
Moreover, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk actively <a href="https://www.benzinga.com/news/24/10/41561298/elon-musk-pumps-more-than-130m-into-trump-and-gop-campaigns">campaigned </a>for Trump, investing over $130 million in Trump and GOP campaigns. Meanwhile, Politico reported that Trump has actively sought celebrity endorsements in all three of his presidential campaigns, including from figures like Kanye West and Kid Rock, who even appeared at key events like the Republican National Convention and his inauguration-eve rally.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45486040/chuck-schumer-raises-concerns-over-trump-and-doge-impact-on-us-coast-guard-after-mexican-ship-collides-with-brook" target="_blank" rel="noreferrer noopener">Chuck Schumer Raises Concerns Over Trump And DOGE Impact On US Coast Guard After Mexican Ship Collides With Brooklyn Bridge: &#8216;We Know They&#8217;ve Been Meddling&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

TSLA

Did Kamala Harris Pay For Endorsements From Beyoncé, Springsteen, Oprah Winfrey? Trump Demands 'Major Investigation'

Transformational Acquisition Increases Sanmina's Scale and End-Market Exposure to Cloud and AI Infrastructure
Planned Divestiture by AMD Creates Preferred NPI Manufacturing Partnership with Sanmina, a Leading IMS Company
Purchase Price of $2.55 Billion Cash and Equity, Plus $450 Million in Contingent Consideration, Totaling Up to $3 Billion
Transaction Expected to be Accretive to Non-GAAP EPS in First Year Post-Close
Sanmina to Host Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT)
SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Sanmina Corporation ("Sanmina") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>), a leading integrated manufacturing solutions company, today announced that it has entered into a definitive agreement to acquire the data center infrastructure manufacturing business of ZT Systems, a leading provider of Cloud and AI infrastructure to the world's largest hyperscalers, from AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). The strategic acquisition further establishes Sanmina's position as an industry-leading, vertically integrated global manufacturing solutions provider that can now also accelerate its customers' at scale deployments of cutting-edge AI systems for the data center.
As a combined company, Sanmina expects to strengthen its leading end-to-end component technology, systems integration and supply chain solutions to deliver even greater value for its customers. ZT Systems' current annual net revenue run-rate is approximately $5 - $6 billion and the outlook ahead is promising as new accelerated compute platforms are launched. In addition, ZT Systems' manufacturing team brings over 30 years of systems integration experience and has evolved into a leading provider of high-performance Cloud and AI infrastructure for hyperscalers. The company's advanced liquid cooling capabilities and manufacturing facilities in New Jersey, Texas and the Netherlands, together with its global supply chain, position it to offer end-to-end systems integration, from components to complete racks, for the Cloud and AI infrastructure ecosystem.

SANM

Sanmina To Acquire Data Center Infrastructure Manufacturing Business Of ZT Systems From AMD In $3B Deal; Transaction Expected To Be Accretive To Non-GAAP EPS In First Year Post-Close

Citigroup analyst Scott Gruber downgrades Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) from Buy to Neutral and announces $6.5 price target.

PTEN

Citigroup Downgrades Patterson-UTI Energy to Neutral, Announces $6.5 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

Reiteration

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025.
RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025.

Altimmune Begins Phase 2 Trial of Pemvidutide for Alcohol Use Disorder With First Patient Enrolled

Macro Economic Events

Economics

Federal Reserve

Bostic Says Number Of Rate Cuts This Year Depends On How Things Turn Out, Details Of Tariffs Will Matter; Leaning More Towards Only One Cut This Year Because It Will Take Time To Understand Tariffs

Loop Capital analyst Alan Gould upgrades Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from Hold to Buy and raises the price target from $430 to $510.

CHTR

Loop Capital Upgrades Charter Communications to Buy, Raises Price Target to $510

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) with a Buy and maintains $3.5 price target.

ASRT

HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $3.5 Price Target

Qualcomm Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) revealed its intentions to manufacture custom data center CPUs, utilizing technology from&nbsp;Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for connection to Nvidia&#8217;s AI chips.
What Happened: Qualcomm&#8217;s future chips will incorporate Nvidia&#8217;s technology, facilitating rapid communication with Nvidia&#8217;s graphics processors (GPUs), a vital part of its AI chip portfolio. This development signifies Qualcomm&#8217;s re-entry into the data center CPU market, a space typically ruled by Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), said the company on Monday at a presentation at Computex in Taipei, Taiwan, reported Reuters.
Previously, Qualcomm had begun developing an Arm-based (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) CPU in partnership with Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), but had to stop due to cost reductions and legal obstacles. However, after bringing on board a team of former Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) chip designers in 2021, Qualcomm has quietly revived its efforts and is once again in talks with Meta regarding a data center CPU.
Qualcomm recently confirmed a partnership with Saudi AI firm Humain to develop a custom data center CPU. "With the ability to connect our custom processors to Nvidia&#8217;s rack-scale architecture, we&#8217;re advancing a shared vision of high-performance energy-efficient computing to the data center," said CEO Cristiano Amon.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45486943/arthur-hayes-forecasts-bitcoin-will-hit-200000-in-next-bull-run-anticipates-revival-of-fortunes-for-this-hated-coin" target="_blank" rel="noreferrer noopener">Arthur Hayes Forecasts Bitcoin Will Hit $200,000 In Next Bull Run, Anticipates Revival Of Fortunes For This &#8216;Hated&#8217; Coin &#8211; Benzinga</a>
Why It Matters: &nbsp;This move comes as part of Qualcomm&#8217;s broader strategy to diversify its revenue streams. Qualcomm aims to <a href="https://www.benzinga.com/news/earnings/25/05/45127498/qualcomm-plans-22-billion-in-non-handset-revenue-by-2029-with-ai-as-its-trojan-horse">generate </a>$22 billion in non-handset revenue by 2029, with AI being a key driver. The collaboration with Nvidia and the development of custom data center CPUs align with this goal. 
Moreover, association with Nvidia's infrastructure is crucial for any company aiming to break into the data center market, given the central role the Jensen Huang-led company&#8217;s semiconductors play in AI. 
Despite delivering Q2 results that <a href="https://www.benzinga.com/news/25/05/45198245/qualcomm-qcom-shares-dip-despite-q2-earnings-beat-whats-going-on">surpassed </a>Wall Street predictions, Qualcomm&#8217;s shares have dipped 4.6% over the past week. The company&#8217;s foray into the data center CPU&nbsp;market could potentially bolster its performance in the stock market.
Qualcomm holds a momentum rating of 28.77% and a growth rating of 59.61%, according to&nbsp;<a href="https://www.benzinga.com/quote/QCOM" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance.
Over the past month, the shares of Qualcomm Inc. surged 12.02%. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/equities/25/05/45486452/jim-cramer-recalls-2011s-6-7-market-decline-after-us-debt-downgrade-says-it-ultimately-meant-not" target="_blank" rel="noreferrer noopener">Jim Cramer Recalls 2011&#8217;s 6.7% Market Decline After US Debt Downgrade, Says It &#8216;Ultimately Meant Nothing:&#8217; Dan Niles Sees Limited Downside Amid Tariff Rollbacks, FOMO</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

INTC

NVDA

QCOM

Qualcomm Re-Enters Data Center CPU Market, Taps Nvidia Tech To Power AI Ambitions

Barclays analyst Seth Sigman upgrades Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from Underweight to Equal-Weight and raises the price target from $131 to $166.

Barclays Upgrades Williams-Sonoma to Equal-Weight, Raises Price Target to $166

HC Wainwright &amp; Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and raises the price target from $27 to $32.

ACAD

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $32

Barclays analyst Eddie Kim downgrades Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) from Equal-Weight to Underweight and lowers the price target from $53 to $28.

Barclays Downgrades Nabors Industries to Underweight, Lowers Price Target to $28

Barclays analyst Benjamin Theurer downgrades BRF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>) from Overweight to Equal-Weight and lowers the price target from $5 to $3.5.

BRFS

Barclays Downgrades BRF to Equal-Weight, Lowers Price Target to $3.5

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) with a Buy and maintains $8 price target.

GANX

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Fed's Bostic Says Moody's Downgrade Will Have Implications For Cost Of Capital, Could Ripple Through Economy; Also Says It Is Unclear If Consumers Can Take On Full Cost Of Tariffs Given State Of Household Balance Sheets And Recent Inflation

Small Cap

Press Releases

/C O R R E C T I O N -- DarioHealth Corp./

Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Growth in B2B Recurring Revenue

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth

Contracts

Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion

DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Penny Stocks

DarioHealth Announces CFO Transition

DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

Comments

DarioHealth

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL